The CDC estimates 93 m adults in the US are at high risk for serious vision loss.
More than 90% of vision loss caused by chronic conditions, including impairment caused by diabetic retinopathy, macular degeneration, and glaucoma, is preventable.
Yet these conditions remain leading causes of blindness--largely due to poor adherence to recommended care.
Lumata Health currently serves thousands of patients suffering from vision-threatening chronic eye conditions through partnerships with ophthalmology clinics and health systems.
Data shows patients supported by Lumata Health's intelligent eye care management platform, which incorporates clinical and psychosocial elements to empower patients to manage their chronic condition throughout their care journey, miss an average of 30% fewer appointments.
Patients are connected with an experienced, certified eye care coordinator that works with them to ensure adherence to their doctor's care plan through ongoing education and addressing barriers to care.
Hadley provides personalized learning opportunities that empower adults with vision loss or blindness to thrive at home, at work, and in their communities.
The Hadley team draws on expertise in vision rehabilitation, digital technology, instructional design, and an advisory panel of more than 1,000 people with vision impairment to deliver a user-centered approach to content creation, resulting in 98% user satisfaction rating across Hadley's library of workshops.
Since relaunching in July 2020, more than 54,000 people have signed up with Hadley, registering nearly 200,000 workshop interactions across all 50 states and 100 countries.
Patients in Lumata's network will be given free access to Hadley resources and assisted through the sign-up process by a Lumata representative to take advantage of all relevant tools and tutorials.
All individuals experiencing vision impairment can access Hadley's services for free by signing up here.
Follow Lumata Health's social channels (Twitter, LinkedIn and Facebook) and Hadley's social channels (Twitter, LinkedIn and Facebook) for the latest news and information.
Lumata Health is a technology-driven healthcare startup company focused on preventing blindness from chronic eye conditions, managing thousands of people at risk of vision loss across the United States.
Founded in 2017 by an ophthalmologist and retina specialist in practice for over 30 years, Stephen R. Fransen, MD, and supported by more than 30 industry luminaries and influencers on its advisory board, Lumata Health aims to stop preventable blindness with a human-led, intelligent care coordination and management platform that's almost always free to the patient.
The company partners with physicians, payers and health systems to offer turnkey care management services provided by eye care experts who are supported by technology and data science.
Lumata Health's programs improve clinical outcomes, patient satisfaction, and clinic staff efficiency by providing between-visit patient assistance and care coordination for patients with chronic eye diseases such as diabetic retinopathy, macular degeneration, glaucoma, and dry eye.
Founded in 1920 by William Hadley, an educator who lost his eyesight later in life, Hadley offers practical help, connection and support free of charge to anyone with a visual impairment, their families and professionals supporting them.
A 501(c) (3) non-profit organization, Hadley is a partner of the National Eye Institute and the National Eye Health Education Program.
Langhua Pharmaceutical passes US FDA's on-site inspection
Arecor signs collaboration deal with global pharma partner
ANI Pharmaceuticals secures FDA approval for ILUVIEN label expansion
Sterotherapeutics launches Phase 2 clinical trial of ST-002 for Cushing's Syndrome
FDA accepts Alvotech and Teva's application for Eylea biosimilar
Owens & Minor launches ByramConnect digital health platform for diabetes management
NLS Pharmaceutics and Kadimastem plan multi-target approach to diabetes
Eton Pharmaceuticals secures US patent for ET-600, protecting formulation through 2044
Bain Capital to acquire Mitsubishi Tanabe Pharma in USD3.3bn deal
Teladoc Health to acquire Catapult Health to enhance integrated care offerings
NLS Pharmaceutics and Kadimastem announce shareholder approval for merger
ImmunoPrecise Antibodies announces development of AI-designed GLP-1 therapies for diabetes